|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Inje University GlaxoSmithKlineKorea |
| Information provided by: | Inje University |
| ClinicalTrials.gov Identifier: | NCT00492414 |
Purpose
Panic disorder(PD)is a disabling psychiatric condition associated with significant impairment in psychosocial, occupational functioning and quality of life, as mentioned by mogotsi et al. So, most patients with panic disorder suffers from the consequences of the impairment in occupational function. This impairment is not only individual problem, but also social one. Since productivity is very important item required to employees, lost productive time among workers with psychiatric illness should be reduced by the proper management. But few data were reported in this field by now.
| Condition | Intervention | Phase |
|
Panic Disorder |
Drug: Paroxetine CR |
Phase IV |
| MedlinePlus related topics: | Panic Disorder |
| ChemIDplus related topics: | Paroxetine Paroxetine hydrochloride Paroxetine Mesylate |
| Study Type: | Interventional |
| Study Design: | Health Services Research, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study |
Eligibility
| Ages Eligible for Study: | 20 Years to 50 Years |
| Genders Eligible for Study: | Both |
Inclusion Criteria:
In female, is eligible to enter this study if she is if
Exclusion Criteria:
Contacts and Locations| Contact: Eun-Joo Jung | +82-2-2270-0940 | menfipro@naver.com |
| Korea, Republic of | |||||
| Seoul Paik Hospital, Inje University | Recruiting | ||||
| Seoul, Korea, Republic of | |||||
| Contact: Eun-Joo Jung +82-2-2270-0940 menfipro@naver.com | |||||
| Inje University |
| GlaxoSmithKlineKorea |
| Principal Investigator: | Jong-Min Woo, Master | Seoul Paik Hospital, Inje University |
More Information
| Study ID Numbers: | COL110010 |
| First Received: | June 26, 2007 |
| Last Updated: | August 7, 2007 |
| ClinicalTrials.gov Identifier: | NCT00492414 |
| Health Authority: | South Korea: Korea Food and Drug Administration (KFDA) |
|
|
|
|